{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:00:54Z","timestamp":1765807254813},"reference-count":26,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2014,11,5]]},"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The study aims at investigating the influence of several factors on the probability of receiving one of the two tiotropium formulations (Respimat or Handihaler).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Drug utilisation study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>All residents in the Region Umbria, Italy, aged \u226545\u2005years, who received prescriptions of tiotropium during 2011\u20132012.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Two groups of patients were studied: (1) incident users of the two tiotropium formulations (ie, without tiotropium prescriptions in the previous 6\u2005months); (2) switchers from Handihaler to Respimat. Users of the two formulations were compared with regard to baseline characteristics and medical history. The adjusted OR of receiving Respimat was estimated for several factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Incident users of the two formulations (4390 participants) had similar characteristics. They were older and with more comorbidities than patients included in randomised control trials (RCTs). Among prevalent users of Handihaler, the probability of switching to Respimat was greater in patients with severe respiratory disease (users of \u22654 respiratory drugs: adjusted OR=4.62; 95% CI 2.46 to 8.69) and among \u03b2-blocker users (adjusted OR=1.76; 95% CI 1.13 to 2.75). Age above 75\u2005years and lipid-lowering drug use reduced the probability of switching. A positive association was also found between neurological conditions and the use of Respimat.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>When starting tiotropium treatment, the choice between the two formulations is weakly affected by comorbidities and chronic obstructive pulmonary disease severity. Instead, these characteristics influence the likelihood of switching from Handihaler to Respimat. Since tiotropium users in clinical practice are more severe than those included in RCTs, further aetiological studies are needed to compare the safety profile of the two formulations in routine care.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2014-006619","type":"journal-article","created":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T01:41:04Z","timestamp":1432604464000},"page":"e006619","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study"],"prefix":"10.1136","volume":"5","author":[{"given":"Francesco","family":"Trotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Da Cas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Rajevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Traversa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,5,25]]},"reference":[{"key":"2024051513040911000_5.5.e006619.1","unstructured":"Global Strategy for Diagnosis, Management, and Prevention of COPD from the Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2013. http:\/\/www.goldcopd.org\/ (accessed 12 May 2014)."},{"key":"2024051513040911000_5.5.e006619.2","unstructured":"Da Cas R , Ruggeri P , Rossi M , et al . Prescrizione farmaceutica in Umbria. Analisi dei dati relativi al 2011. Rapporti ISTISAN 13\/11. Roma: Istituto Superiore di Sanit\u00e0; 2013:1\u2013133."},{"key":"2024051513040911000_5.5.e006619.3","unstructured":"Spiriva\u00ae Summary of Product Characteristics. Banca dati farmaci. Agenzia Italiana del Farmaco. https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/pages\/home.jsp (accessed 12 May 2014)."},{"key":"2024051513040911000_5.5.e006619.4","unstructured":"Spiriva\u00ae Respimat\u00ae Summary of Product Characteristics. Banca dati farmaci. Agenzia Italiana del Farmaco. https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/pages\/home.jsp (accessed 12 May 2014)."},{"key":"2024051513040911000_5.5.e006619.5","first-page":"251","article-title":"Use of Respimat Soft Mist inhaler in COPD patients","volume":"1","author":"Anderson","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024051513040911000_5.5.e006619.6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/COPD.S3391","article-title":"Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler","volume":"4","author":"Hodder","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024051513040911000_5.5.e006619.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.06.004"},{"key":"2024051513040911000_5.5.e006619.8","first-page":"197","article-title":"Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies","volume":"5","author":"Bateman","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024051513040911000_5.5.e006619.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805800"},{"key":"2024051513040911000_5.5.e006619.10","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/bmj.d3215","article-title":"Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomized controlled trials","volume":"342","author":"Singh","year":"2011","journal-title":"BMJ"},{"key":"2024051513040911000_5.5.e006619.11","doi-asserted-by":"crossref","unstructured":"Karner C , Chong J , Poole P . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;(7):CD009285. doi:10.1002\/14651858.CD009285.pub2","DOI":"10.1002\/14651858.CD009285.pub2"},{"key":"2024051513040911000_5.5.e006619.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201926"},{"key":"2024051513040911000_5.5.e006619.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303342"},{"key":"2024051513040911000_5.5.e006619.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7390"},{"key":"2024051513040911000_5.5.e006619.15","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMe1310107","article-title":"More than just reassurance on tiotropium safety","volume":"369","author":"Jenkins","year":"2013","journal-title":"N Engl J Med"},{"key":"2024051513040911000_5.5.e006619.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00042213"},{"key":"2024051513040911000_5.5.e006619.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00042113"},{"key":"2024051513040911000_5.5.e006619.18","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202482"},{"key":"2024051513040911000_5.5.e006619.19","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201275"},{"key":"2024051513040911000_5.5.e006619.20","unstructured":"Pulmonary-Allergy Drugs Advisory Committee. US Food and Drug Administration. Clinical briefing document, November 19 2009. Overview of the FDA background materials for an efficacy supplement for NDA# 21\u2013395, for the approved product Spiriva HandiHaler (tiotropium bromide inhalation powder), for the reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD). http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/pulmonary-allergydrugsadvisorycommittee\/ucm190463.pdf (accessed 12 May 2014)."},{"key":"2024051513040911000_5.5.e006619.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005813"},{"key":"2024051513040911000_5.5.e006619.22","unstructured":"Gruppo di lavoro OsMed. L'uso dei farmaci in Italia. Rapporto nazionale anno 2011. Roma: Il Pensiero Scientifico Editore; 2012:1\u2013335. http:\/\/www.agenziafarmaco.gov.it\/sites\/default\/files\/1_-_rapporto_osmed_2011.pdf (accessed 12 May 2014)."},{"key":"2024051513040911000_5.5.e006619.23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0194"},{"key":"2024051513040911000_5.5.e006619.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2012.10.008"},{"key":"2024051513040911000_5.5.e006619.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.01.036"},{"key":"2024051513040911000_5.5.e006619.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403086"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-006619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T20:26:04Z","timestamp":1715804764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-006619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,25]]},"published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1136\/bmjopen-2014-006619"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-006619","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}